These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9870683)
41. Renal cell carcinoma in South Korea: a multicenter study. Kim H; Cho NH; Kim DS; Kwon YM; Kim EK; Rha SH; Park YW; Shim JW; Lee SS; Lee SN; Lee J; Lee JS; Lee TJ; Jung SJ; Jung SH; Chung JH; Cho HY; Joo HJ; Choi YJ; Choi C; Han WS; Hur B; Ro JY; Hum Pathol; 2004 Dec; 35(12):1556-63. PubMed ID: 15619217 [TBL] [Abstract][Full Text] [Related]
42. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma. Young JR; Coy H; Kim HJ; Douek M; Lo P; Pantuck AJ; Raman SS AJR Am J Roentgenol; 2017 Apr; 208(4):812-819. PubMed ID: 28125273 [TBL] [Abstract][Full Text] [Related]
43. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Furge KA; Chen J; Koeman J; Swiatek P; Dykema K; Lucin K; Kahnoski R; Yang XJ; Teh BT Cancer Res; 2007 Apr; 67(7):3171-6. PubMed ID: 17409424 [TBL] [Abstract][Full Text] [Related]
44. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification. Zhou M; Yang XJ; Lopez JI; Shah RB; Hes O; Shen SS; Li R; Yang Y; Lin F; Elson P; Sercia L; Magi-Galluzzi C; Tubbs R Am J Surg Pathol; 2009 Dec; 33(12):1840-9. PubMed ID: 19898225 [TBL] [Abstract][Full Text] [Related]
45. Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. Konda R; Sato H; Hatafuku F; Nozawa T; Ioritani N; Fujioka T J Urol; 2004 Jun; 171(6 Pt 1):2166-70. PubMed ID: 15126778 [TBL] [Abstract][Full Text] [Related]
46. [Expression of HGF and its receptor c-Met in renal cell carcinoma]. Shi BB; Zhang XH; Wang HJ; Li HZ Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):356-8. PubMed ID: 15312347 [TBL] [Abstract][Full Text] [Related]
47. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269 [TBL] [Abstract][Full Text] [Related]
48. Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation-independent mechanisms of inactivation. Wethkamp N; Ramp U; Geddert H; Schulz WA; Florl AR; Suschek CV; Hassan M; Gabbert HE; Mahotka C Eur J Cancer; 2006 Jan; 42(2):264-74. PubMed ID: 16386893 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor. Schiefer AI; Mesteri I; Berghoff AS; Haitel A; Schmidinger M; Preusser M; Birner P Histopathology; 2015 Dec; 67(6):799-805. PubMed ID: 25847631 [TBL] [Abstract][Full Text] [Related]
50. Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma. Cox R; Vang R; Epstein JI Am J Surg Pathol; 2014 May; 38(5):713-8. PubMed ID: 24441657 [TBL] [Abstract][Full Text] [Related]
51. Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes. Clifford SC; Czapla K; Richards FM; O'Donoghue DJ; Maher ER Br J Cancer; 1998 May; 77(9):1420-8. PubMed ID: 9652757 [TBL] [Abstract][Full Text] [Related]
52. Accuracy of fine needle aspiration in distinguishing subtypes of renal cell carcinoma. Renshaw AA; Lee KR; Madge R; Granter SR Acta Cytol; 1997; 41(4):987-94. PubMed ID: 9250289 [TBL] [Abstract][Full Text] [Related]
53. Expression of CD9/motility-related protein 1 (MRP-1) in renal parenchymal neoplasms: consistent expression in papillary and chromophobe renal cell carcinomas. Kuroda N; Inoue K; Guo L; Miyazaki E; Hayashi Y; Naruse K; Toi M; Hiroi M; Shuin T; Enzan H Hum Pathol; 2001 Oct; 32(10):1071-7. PubMed ID: 11679941 [TBL] [Abstract][Full Text] [Related]
57. Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade. Barresi V; Ieni A; Bolignano D; Magno C; Buemi M; Barresi G Oncol Rep; 2010 Aug; 24(2):305-10. PubMed ID: 20596614 [TBL] [Abstract][Full Text] [Related]
58. Expression of vitamin D3 receptor in kidney tumors. Liu W; Tretiakova M; Kong J; Turkyilmaz M; Li YC; Krausz T Hum Pathol; 2006 Oct; 37(10):1268-78. PubMed ID: 16949927 [TBL] [Abstract][Full Text] [Related]
59. The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review. Chen S; Zhu Y; Cui J; Wang Y; Xia Y; Song J; Cheng S; Zhou C; Zhang D; Zhang B; Shi B Urol Oncol; 2017 Aug; 35(8):532.e15-532.e23. PubMed ID: 28427859 [TBL] [Abstract][Full Text] [Related]
60. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Stumm G; Eberwein S; Rostock-Wolf S; Stein H; Pomer S; Schlegel J; Waldherr R Int J Cancer; 1996 Feb; 69(1):17-22. PubMed ID: 8600053 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]